p53 (EP9) Rabbit Monoclonal Primary Antibody
Specialties: Anatomic Pathology
Anti-p53 tumor suppressor protein antibody recognizes a 53 kDa phosphoprotein, identified as p53 suppressor gene product. It reacts with the mutant as well as wild type p53, although significant accumulation of the mutant form of p53 protein due to longer half-life is the basis for the test using the IHC technique.1 Nuclear staining with this antibody has been shown in breast carcinoma, lung carcinoma, colorectal carcinoma, and urothelial carcinoma.2-8
- Dabbs DJ. Diagnostic Immunohistochemistry. Third Edition. Philadelphia, PA: Saunders. 2006. p 701-2.
- Mauri FA, et al. Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up. Int J Oncol. 1999; 15:1137-47.
- Caffo O, et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res. 1996; 2:1591-9.
- Bebenek M, et al.Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. Anticancer Res. 1998; 18:619-23.
- Midulla C, et al. Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer. Anticancer Res. 1999; 19:4033-7.
- Quinlan DC, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992; 52:4828-31.
- Zeng ZS, et al. p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. J Clin Oncol. 1994; 12:2043-50.
- McKenney JK, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001; 25:1074-8.
Specifications
- Reactivity: paraffin
- Control: Colorectal carcinoma (Nuclear); Urothelial carcinoma (Nuclear); Ovarian serous carcinoma (Nuclear); Breast ductal carcinoma in-situ (Nuclear)
- Dilution Range: 1:100-1:200 *
Package Inserts
IFU
- IVD Rev. 1.0 (CMC45332010)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 453R-24 |
| 0.5 mL concentrate | 453R-25 |
| 1.0 mL concentrate | 453R-26 |
| 1.0 mL predilute ready-to-use | 453R-27 |
| 7.0 mL predilute ready-to-use | 453R-28 |
For in vitro diagnostic (IVD) use in Canada
| 0.1 mL concentrate | 453R-24 |
| 0.5 mL concentrate | 453R-25 |
| 1.0 mL concentrate | 453R-26 |
| 1.0 mL predilute ready-to-use | 453R-27 |
| 7.0 mL predilute ready-to-use | 453R-28 |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 453R-24 |
| 0.5 mL concentrate | 453R-25 |
| 1.0 mL concentrate | 453R-26 |
| 1.0 mL predilute ready-to-use | 453R-27 |
| 7.0 mL predilute ready-to-use | 453R-28 |
For research use only (RUO) in Japan
| 0.1 mL concentrate (RUO) | 453R-24-RUO |
| 0.5 mL concentrate (RUO) | 453R-25-RUO |
| 1.0 mL concentrate (RUO) | 453R-26-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 453R-27-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 453R-28-RUO |
To request information on this product in additional countries, please click the button below.
